Silence Therapeutics Plc Adr (SLN)

Feb 20, 2025

BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.

Feb 20, 2025

Feb 11, 2025

Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 11, 2025

Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News

Feb 11, 2025

Feb 11, 2025

Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex

Feb 11, 2025

Feb 10, 2025

Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater

Feb 10, 2025

Feb 03, 2025

Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Feb 03, 2025

Feb 03, 2025

Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com

Feb 03, 2025

Feb 03, 2025

H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa

Feb 03, 2025

Jan 07, 2025

European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN

Jan 07, 2025

Dec 18, 2024

Top 3 Health Care Stocks That May Explode In Q4 - Benzinga

Dec 18, 2024

Dec 17, 2024

Silence Therapeutics' SWOT analysis: stock's potential in RNAi therapeutics - Investing.com

Dec 17, 2024

Dec 10, 2024

Silence Therapeutics' SWOT analysis: RNAi stock poised for growth amid clinical progress - Investing.com India

Dec 10, 2024

Dec 09, 2024

Silence Therapeutics announces additional results from SANRECO study - TipRanks

Dec 09, 2024

Nov 24, 2024

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - MSN

Nov 24, 2024

Nov 20, 2024

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study - Yahoo Finance

Nov 20, 2024

Nov 20, 2024

United States shares mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com India

Nov 20, 2024

Nov 19, 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com

Nov 19, 2024

Nov 19, 2024

Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - TipRanks

Nov 19, 2024

Nov 19, 2024

SILENCE THERAPEUTICS PLC SPONSORED ADR trading resumes - TipRanks

Nov 19, 2024

Nov 19, 2024

Top 3 Health Care Stocks You'll Regret Missing In Q4 - Benzinga

Nov 19, 2024

Nov 17, 2024

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Nov 14, 2024

Silence Therapeutics: Rising Assets Amid Growing Losses - TipRanks

Nov 14, 2024

Oct 21, 2024

Novartis Gets CHMP Recommendation for Kisqali in Broader Population - Yahoo Finance

Oct 21, 2024

Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - 新浪香港

Oct 16, 2024

Oct 01, 2024

ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty - Yahoo Finance

Oct 01, 2024

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 30, 2024

Silence Therapeutics's SWOT analysis: stock poised for growth in genetic medicine - Investing.com

Sep 30, 2024

Sep 25, 2024

Biogen's Lupus Candidate Meets Key Goals in Phase III Study - Yahoo Finance

Sep 25, 2024

Sep 24, 2024

CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance

Sep 24, 2024

Sep 02, 2024

It makes sense and dollars to buy Silence Therapeutics Plc ADR (SLN) stock - SETE News

Sep 02, 2024

Sep 02, 2024

Silence Therapeutics Plc ADR (SLN) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News

Sep 02, 2024

Sep 02, 2024

What Did We Find About Insider Trading At Silence Therapeutics Plc ADR (NASDAQ: SLN)? - Stocks Register

Sep 02, 2024

Sep 02, 2024

Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data - Investing.com UK

Sep 02, 2024

Aug 30, 2024

H.C. Wainwright reiterates Buy on Silence Therapeutics stock amid strong trial results By Investing.com - Investing.com South Africa

Aug 30, 2024

Aug 29, 2024

GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years - Yahoo Finance

Aug 29, 2024

Aug 07, 2024

The 3 Best Gene Editing Stocks to Buy in August 2024 - Markets Insider

Aug 07, 2024

Jul 12, 2024

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last? - Yahoo Finance

Jul 12, 2024

Jun 06, 2024

Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates - Yahoo Finance

Jun 06, 2024

Feb 16, 2024

Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains? - Yahoo Finance

Feb 16, 2024

Dec 15, 2023

Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - MSN

Dec 15, 2023

Dec 06, 2023

Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect? - Yahoo Finance

Dec 06, 2023

Nov 01, 2023

symbol__ Stock Quote Price and Forecast - CNN

Nov 01, 2023

Feb 06, 2023

Silence Therapeutics Plc ADR (SLN-Q) QuotePress Release - The Globe and Mail

Feb 06, 2023

Dec 30, 2020

Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga

Dec 30, 2020

Oct 06, 2020

The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation - Yahoo Finance

Oct 06, 2020

Dec 14, 2017

Silence Therapeutics (SLN) - Zacks Investment Research

Dec 14, 2017

Jul 27, 2011

ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN

Jul 27, 2011